Quick Answer
Upstream Bio, Inc. reported Net Income Loss of -$143.44 million for the year ending 2025.
- Upstream Bio, Inc. showed a decrease of -128.4% in Net Income Loss from 2024 to 2025.
- This data is from Upstream Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$3.06 million | Q2 2023: -$2.54 million | Q3 2023: -$3.10 million | Q1 2024: -$10.89 million | Q2 2024: -$14.68 million | Q3 2024: -$15.99 million | Q1 2025: -$27.27 million | Q2 2025: -$39.97 million | Q3 2025: -$33.75 million.
- Over the full 3 years of available data (2023 to 2025), Upstream Bio, Inc.'s Net Income Loss has declined by 598.5%.
- Historical annual values: Fiscal year 2025: -$143.44 million | Fiscal year 2024: -$62.81 million | Fiscal year 2023: -$20.54 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: